Close Menu

Cofactor Genomics

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.

The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.

Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.

St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.

Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.

The financing follows Cofactor's launch of Pinnacle, an RNA-based oncology assay and the company's first product since a strategic refocusing.

The Pinnacle assay for gene fusions and gene expression in tumor samples is the first in Cofactor's new line of clinical RNA-sequencing assays.

The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.

The companies will combine Cofactor's RNA-seq know-how with SII's big data analytics offerings to provide services for pharmaceutical research customers.

The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.